搜索
 > 【4-1BB】重组蛋白信息

4-1BB信息

英文名称:Tumor necrosis factor receptor superfamily member 9
中文名称:肿瘤坏死因子受体超家族成员9
靶点别称:Tumor necrosis factor receptor superfamily member 9,T-cell antigen ILA,CD_antigen=CD137,ILA,TNFRSF9,CDw137,CD137 ,T-cell antigen 4-1BB homolog,4-1BB ligand receptor
上市药物数量:0
临床药物数量:16
最高研发阶段:临床二期

4-1BB产品列表

 
评论(1)
41B-H5227|Human 4‑1BB / TNFSF9 Protein, His Tag
  1. 189XXXXXXX4
  2. 0人赞
  3. 主要用于筛选抗体,通过样品与购买的抗原的ELISA蛋白水平的结合活性,检测抗体样品活性水平,进而为细胞水平做数据基础。
  4. >
  5. 2019-10-11
 

4-1BB Molecule Synonym Name

TNFRSF9,4-1BB,CD137,CDw137,ILA

4-1BB 分子背景

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

4-1BB 参考文献

4-1BB临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
ALG.APV-527 ALG.APV-527; ADC-1016; ATOR-1016 临床前 Aptevo, Alligator Bioscience 癌症
PRS-344 PRS-344; PRS-344/ONC0055 临床前 Pieris Pharmaceuticals 癌症
LVGN-6051 LVGN-6051 临床一期 礼进生物 癌症 详情
ATOR-1017 ATOR-1017 临床一期 Alligator Bioscience 转移性癌症 详情
ADG-106 ADG-106 临床一期 天演药业 实体瘤, 非霍奇金淋巴瘤 详情
Utomilumab PF-05082566; PF-2566; PF-5082566 临床二期 辉瑞, MorphoSys 乳腺癌, 口咽癌 详情
RG-7827 FAP-4-1BBL; FAP-4-1BBL FP; RG-7827 临床一期 罗氏 实体瘤
AGEN-2373 AGEN-2373 临床一期 Agenus 癌症 详情
Delolimogene mupadenorepvec LOAd-703 临床二期 Uppsala University, Lokon Pharma 结肠直肠癌, 卵巢癌, 胰腺癌, 胆道癌 详情
ES101 ES101 临床一期 Inhibrx, 科望医药 实体瘤 详情
MCLA-145 MCLA-145 临床一期 Incyte, Merus 实体瘤 详情
Urelumab BMS-663513; BMS-66513 ,BMS663513 临床二期 百时美施贵宝, 小野制药 B细胞淋巴瘤, 慢性淋巴细胞白血病, 实体瘤, 多发性骨髓瘤, 结肠直肠癌, 头颈癌 详情
PRS-343 PRS-343,PRS 343,PRS343 临床一期 Pieris Pharmaceuticals 实体瘤 详情
INBRX-105 INBRX-105 临床一期 Inhibrx 实体瘤, 非霍奇金淋巴瘤, 霍奇金淋巴瘤 详情
GEN-1046 DuoBody-PD-L1x4-1BB; GEN1046; PD-L1x4-1BB 临床二期 Genmab, BioNTech 三阴性乳腺癌, 非小细胞肺癌, 子宫内膜癌症, 尿路上皮癌, 头颈部鳞状细胞癌, 实体瘤, 宫颈癌 详情
MP-0310 MP-0310 临床一期 Molecular Partners 实体瘤, 癌症 详情

消息提示

请输入您的联系方式,再点击提交!

确定